Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Determination of Minimal Important Difference for the Glittre-ADL Test and London Chest Activity of Daily Living Scale in Patients With COPD
Background: The ability to perform activities of daily living (ADL) in patients with chronic obstructive pulmonary disease is often impaired. Glittre-ADL Test has been used to assess limitations in ADL, and it seems to be responsive to intervention. However, the minimal detectable change for Glittre-ADL Test remains unknown. Design: Non-controlled before and after study. Setting: The study will be conducted in an outpatient pulmonary rehabilitation program in Florianopolis, Brazil. Subjects: Patients with COPD (GOLD II-IV). Interventions: Pulmonary rehabilitation program based on physical training, conducted over 24 sessions supervised, three times a week, including aerobic training in treadmill and localized training for upper limbs and lower limbs. Main measures: Glittre ADL-Test performance, six-minute walk test performance, London Chest Activity of Daily Living score, Modified Medical Research Council score, COPD Assessment Test score, Saint George Respiratory Questionnaire score before and after the pulmonary rehabilitation program.
Assigned Interventions: Pulmonary rehabilitation program (PRP) was conducted according to the
guidelines of the American Thoracic Society/European Respiratory Society (ATS/ERS). Physical
training was conducted over 24 sessions supervised, three times a week. The program included
aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6
on the modified Borg scale) and localized training for upper limbs with free weights or
elastic bands (movements performed based on the proprioceptive neuromuscular facilitation
diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and
triceps sural) with free weights and/or in the bodybuilding station .
Pulmonary function test: Spirometry will be performed before the PRP, and it will be in
accordance with ATS/ERS standards in order to provide the level of pulmonary obstruction and
severity of disease. The predicted values will be calculated with the equations derived from
Brazilian population.
Glittre-ADL Test: The patients will be instructed to complete five laps on the follow circuit
as quickly as possible: from a sitting position, the subject stands up and walks along a flat
10-m long course, in the middle of which there is a two-step ladder (each step 17 cm high x
27 cm deep) to be climbed; after completing the 10 m, the subject faces a shelf containing
three 1-kg objects positioned on the top shelf (shoulder height) and moves them one by one to
the bottom shelf (waist height) and then to the floor; the objects are then returned to the
bottom shelf and finally to the top shelf again; the subject walks back, climbing up and down
the steps, until reaching the starting point (chair), sits down and immediately begins the
next lap. The subjects carry a weighted backpack (2.5 kg for women, 5.0 kg for men). Two
Glittre-ADL Tests will be conducted before and after the PRP.
Six minute walk test (6MWT): The patients will be instructed to walk in order to perform the
largest distance during six minutes. The walking speed will be selected by the patient,
according to the guidelines of the ATS. Two 6MWTs will be conducted before and after the PRP.
London Chest Activity of Daily Living scale: Patients will be asked about their perception of
limitation in activities of daily living, using the London Chest Activity of Daily Living
scale (LCADL) before and after the PRP.
Modified Medical Research Council scale: Patients will be asked about their perception of
dyspnea, using the modified Medical Research Council scale before and after the PRP.
Saint George Respiratory Questionnaire: Patients will be asked about their perception of
health-related quality of life, using the Saint George Respiratory Questionnaire before and
after the PRP.
COPD Assessment Test (CAT): Patients will be asked about their perception of the impact of
COPD (cough, sputum, dyspnea, and chest tightness) on health status, using CAT before and
after the PRP.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|